Product Details
Zofran
Ondansetron Hydrochloride8 mg
Tablet
DIN/PIN/NPN
02213575
Manufacturer
Novartis Pharma Canada Inc.
Formulary Listing Date
1997-01-20
Unit Price
NA
Amount MOH Pays
NA
Coverage Status
Not a Benefit
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
A04AA01
Interchangeable Products
| DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
|---|---|---|---|
| 02213575 | Zofran | NA | NA |
| 02376105 | Septa-Ondansetron | 5.1110 | 3.8840 |
| 02274329 | Sandoz Ondansetron | 5.1110 | 3.8840 |
| 02258196 | PMS-Ondansetron | 5.1110 | 3.8840 |
| 02421410 | Ondansetron | 4.9930 | 3.8840 |
| 02417847 | Nat-Ondansetron | 5.1110 | 3.8840 |
| 02297876 | Mylan-Ondansetron | 5.1110 | 3.8840 |
| 02305267 | Mint-Ondansetron | 5.1110 | 3.8840 |
| 02371758 | Mar-Ondansetron | 5.1110 | 3.8840 |
| 02313693 | Jamp-Ondansetron | 5.1110 | 3.8840 |
| 02288192 | Apo-Ondansetron | 5.1110 | 3.8840 |
| 02296357 | Teva-Ondansetron | 5.1110 | 3.8840 |
| 02478935 | Accel-Ondansetron | 3.8840 | 3.8840 |
| 02541432 | Ondansetron | 5.1110 | 3.8840 |
LU Clinical Criteria
NOEAP Criteria
| Therapeutic Class | Reimbursement Criteria |
|---|---|
| Unclassified EAP Drugs | These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – August 8, 2023 Edition Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding. |